Alexandrite laser is one of the most common methods of hair removal. Its utilization is gradually increasing due to easy accessibility and high effectiveness. However, the disuse of protective goggles during the application of this laser is a serious problem. In this case report, we presented a 35-year-old male patient who had foveal injury by alexandrite laser. The inflammatory process secondary to the foveal injury and subsequent macular edema were treated with Ozurdex because of its potent antiedematous effect.
Introduction
Alexandrite laser (755 nm) is one of the most common methods of hair removal. Its utilization is gradually increasing due to easy accessibility and high effectiveness. However, the disuse of protective goggles during the application of this laser is a serious problem. Alexandrite laser light is visible, and it is known that ocular injuries may occur during the use of alexandrite laser when protective goggles are not worn [1, 2] . Still, foveal injuries by alexandrite laser are rare. Herein, we reported a case with accidental foveal injury and subsequent macular edema secondary to alexandrite laser contact, treated with an intravitreal Ozurdex implant.
A 35-year-old male patient presented to our clinic complaining of a scotoma in the right eye, which had begun 2 h after looking at a laser probe for a few seconds in an esthetics clinic. The patient underwent full ophthalmic examination. Best corrected visual acuity (BCVA) was 10/10 in both eyes. Anterior segment examination was unremarkable. Fundus examination showed a pale, white and sharply circumscribed laser spot lesion localized at the inferior nasal foveal region, involving the central foveola. A visual field test (Humphrey, Zeiss, Germany) displayed a scotoma consistent with the affected region. A hypofluorescent lesion, which was in accordance with the round laser spot, was detected in the early and late phases of fundus fluorescein angiography (Canon Inc., Tokyo, Japan). An intense increase in reflectance in the region of the spot was also identified on optic coherence tomography (OCT; SLO, Optos, Dunfermline, UK). All examinations of the left eye were unremarkable. A topical steroid was chosen as initial treatment.
There was no change in the findings at the first control visit after 1 week. However, at the second week, the BCVA of the patient had decreased to 3/10, and edema and hemorrhage had occurred around the lesion. OCT demonstrated intra-and subretinal edema as well as tissue disruption within the injured area ( fig. 1 ). Thus, intravitreal Ozurdex (Allergan, Inc., Irvine, Calif., USA) therapy was decided on, based on its rapid antiedematous effect.
Ozurdex was implanted via the pars plana region with its specific cartridge in the operating room. Topical antibiotics were given after the injection. BCVA increased to 4/10, 1 week after the injection. An intraocular pressure elevation (35 mm Hg) which was successfully controlled by a topical antiglaucomatous agent occurred.
One month after the injection, BCVA was 20/30 despite a hemorrhage around the injured area on fundus examination ( fig. 2) . At month 3, BCVA had increased to 20/20. OCT showed decreased macular edema and a hyperreflectance scar in the affected area ( fig. 3, fig.  4) . A visual field test demonstrated no change in the scotoma of the patient.
Discussion
It is known that alexandrite laser causes a temperature increase and subsequent coagulation necrosis in melanin-containing tissues, which is termed 'selective photothermolysis' [3] . This temperature rise might cause burns, pigmentation changes, and erythema in surrounding tissues [4] . There are two types of eye injuries associated with alexandrite laser. The first type are anterior segment complications such as uveitis, pupillary distortion [1] , iris atrophy [2] , and cataract, which can occur due to laser applications to the face with closed eyes. The second type are posterior segment complications such as macular hole [5] and macular scar [6] caused by the direct effect of the laser beam on the retina while the eyes are open.
The Ozurdex intravitreal implant is composed of a biodegradable copolymer of lactic and glycolic acids containing micronized dexamethasone [7] . The drug-copolymer complex gradually releases dexamethasone that transforms into glycolic and lactic acids after the injection and eventually into water and carbon dioxide [8] . After intravitreal injection, the Ozurdex implant reduces the vitreous levels of several mediators which cause disruption of the blood-retinal barrier (i.e., vascular endothelial growth factor) and accordingly diminishes the vascular permeability. Ozurdex is frequently used in the treatment of macular edema due to diabetes mellitus, retinal vein occlusion, and noninfectious uveitis. 
